alpha-Oxidation of the branched-chain
fatty acid,
phytanic acid, is defective in patients with
Refsum's disease, the disorders of peroxisome biogenesis (e.g.,
Zellweger syndrome), and in
rhizomelic chondrodysplasia punctata. 3H-Release from [2,3-3H]
phytanic acid, which is impaired in cultured skin fibroblasts from these patients, was investigated in rat liver peroxisomes. Cofactors necessary for optimal 3H-release,
ATP, Mg2+, and
coenzyme A, were also necessary for optimal
acyl-CoA synthetase activity, suggesting that the substrate for 3H-release might be
phytanoyl-CoA.
5,8,11,14-Eicosatetraynoic acid (
ETYA), an inhibitor of
long-chain acyl-CoA synthetase activity, blocked
phytanoyl-CoA synthesis as well as 3H-release from [2,3-3H]
phytanic acid in a dose-dependent manner. However, this inhibitor had little effect on 3H-release from [2,3-3H]
phytanoyl-CoA. Tetradecylglycidic
acid (TDGA) inhibited 3H-release from [2,3-3H]
phytanic acid in peroxisomal but not in mitochondrial fractions from rat liver. This agent inhibited 3H-release from [2,3-3H]
phytanic acid and [2,3-3H]
phytanoyl-CoA equally. In contrast to
ETYA, which appeared to decrease 3H-release as a consequence of
synthetase inhibition, TDGA appeared to act directly on the
enzyme catalyzing 3H-release. This
enzyme was partially purified from rat liver. The purified
enzyme, which did not possess
phytanoyl-CoA synthetase activity, catalyzed
tritium release from [2,3-3H]
phytanoyl-CoA. This
enzyme catalyzed 3H-release from [2,3-3H]
phytanic acid only if a source of
phytanoyl-CoA synthetase was present. We conclude that in rat liver peroxisomes,
phytanic acid must be activated to its
coenzyme A derivative prior to subsequent alpha-oxidation.